ALGS

NASDAQ 已收盘

Aligos Therapeutics

1.22 USD
▼-0.03-2.40%
盘后 1.17 -3.74%
2026-11-20
市值
$7.62M
市盈率
—
EPS
-6.37
股息率
—
52 周区间
1.18 – 13.69
成交量
106.83K
Beta
2.43
目标价
36.88
52W 低 1.1852W 高 13.69
价格走势

公司简介

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG‑055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG‑097558, a small molecule ritonavir‑free pan‑coronavirus protea...